Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 2,774 shares, a decrease of 83.3% from the August 15th total of 16,627 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ? days.
Innate Pharma Price Performance
Shares of IPHYF remained flat at $1.65 during mid-day trading on Friday. Innate Pharma has a one year low of $1.37 and a one year high of $2.25. The stock has a 50-day simple moving average of $1.65 and a two-hundred day simple moving average of $1.71.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
See Also
- Five stocks we like better than Innate Pharma
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
